Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 5, 2025Neuropsychopharmacology ReportsOpen Access

The Impact of Adjunctive Aripiprazole on Olanzapine‐Induced Metabolic Adverse Effects in Patients With Schizophrenia: A Systematic Review

View Full Paper
Ask AI
Bookmark
Share

Authors

SSStephen SimmonsSSSoban Sadiq

Discussion

Loading...

Member takes

Overview

Systematic review reports aripiprazole may decrease metabolic issues in schizophrenia, suggesting metabolic advantages.

Key Points

  • Adjunctive aripiprazole may help reduce triglycerides and induce weight loss in patients taking olanzapine.
  • Significant reduction in fasting triglycerides was reported across multiple studies, indicating a consistent positive effect.
  • The systematic review included diverse study designs, highlighting the robustness of findings with respect to metabolic parameters.
  • Psychiatric symptoms remained stable while metabolic improvements were observed, suggesting aripiprazole's safety in schizophrenia management.

Cite This Study

Simmons et al. (2025) studied this question.

synapsesocial.com/papers/68c23966b210217d6477c19fhttps://doi.org/10.1002/npr2.70046
View Full Paper
Ask AI
Bookmark
Share